CNS prophylaxis in patients with DLBCL: Lymphoma Subcommittee of the Argentinian Society of Hematology experience

Le résumé fourni par la source

A multicenter retrospective study from Argentina shows the clinical management and limitations of CNS prophylaxis in patients with DLBCL. Central nervous system (CNS) relapse in patients with diffuse large B cell lymphoma (DLBCL) is an infrequent event and the efficacy of strategies currently used to prevent it, has been challenged. This retrospective study involved two hundred sixty-two patients with DLBCL and CNS prophylaxis. Two hundred and seven (79%) patients received intrathecal therapy (ITT), 34 (13%) high doses of methotrexate (HDMTX) and 21 (8%) both. Twenty patients (7.7%) had CNS relapse with an incidence of 2.8%, 5.8% and 7.7% at 6, 12 and 24 months, respectively. No difference according to type of prophylaxis was found. OS and PFS for the entire cohort at 6, 12, and 24 months were 94% and 84%, 83% and 71%, 62% and 55%, respectively. ITT was the most commonly used prophylactic strategy, despite international guidelines favoring HD-MTX. We describe an incidence of 7.7% of CNS relapse with no difference according to type of prophylaxis. The clinical benefit of CNS prophylaxis remains an area of uncertainty; prospective studies with sufficient power are required to determine the benefits of these strategies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.